Michael Makris on Japan’s Breakthrough FVIII Variants for Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Important paper from Japan published in Blood.
The authors have developed FVIII variants with increased specific activity, which can potentially be used for gene therapy in hemophilia A.
These would be the equivalent of the Padua variant for FIX and can be used at much lower doses.
Even when used at 1/30th of the dose of Roctavian in macaques, supraphysiological FVIII levels were achieved.
No human studies yet.”
Read the full article here.
Article: Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy
Authors: Yuji Kashiwakura, Yuto Nakajima, Kio Horinaka, Tiago J. S. Lopes, Yuma Furuta, Yuki Yamaguchi, Nemekhbayar Baatartsogt, Morisada Hayakawa, Yuko Katakai, Susumu Uchiyama, Osamu Nureki, Keiji Nogami, Tsukasa Ohmori
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 29, 2026, 07:12Matteo Foschi: Is There a Benefit to Switching DOACs After Breakthrough Stroke?
-
Apr 29, 2026, 07:02Enrico Ferro: Stroke Risk in PFA vs Radiofrequency Ablation
-
Apr 29, 2026, 06:03Proud to Recognize 6 Early Career Investigators as the Recipients of the 2026 JTH Editors’ Awards – JTH
-
Apr 29, 2026, 05:55On Hemophilia Care Advances, Collaboration and Access in India at IHC X 2026 – Hemophilia Federation India
-
Apr 29, 2026, 05:46Rajendra Tapadia: Strengthening Last-Mile Hemophilia Care Through Structured Community Outreach
-
Apr 29, 2026, 05:37Masoabi Sefojane: Whose Realities Shape Global Priorities in Hemophilia Care?
-
Apr 29, 2026, 05:24Filippo Cademartiri: Mandatory Reading for Anyone Who Mistakes Expertise for Certainty
-
Apr 29, 2026, 02:52Fengqian Chen: Another Reality Check for the Factor XI Inhibitor Race – Novartis’ Abelacimab Setback
-
Apr 29, 2026, 02:18Arnaud Baldivia: Peri-Procedural Stroke – An Underestimated Emergency in the Operating Room and in the ICU